FASN and ovarian cancer: To further examine whether FASN and CPT1A are involved in oncogenic effects mediated by the NF-κB pathway in OCM-treated ovarian cancer, orlistat (FASN inhibitor) and etomoxir (CPT1A inhibitor) were employed to block the respective function of FASN and CTP1A in ovarian cancer cells.